NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SAGE shares have increased by 9.7% and is now trading at $46.42.
View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SAGE Therapeutics.

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for SAGE Therapeutics.

SAGE Therapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.17) by $0.73. The biopharmaceutical company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.81 million. SAGE Therapeutics had a negative return on equity of 63.13% and a negative net margin of 7,406.75%. The firm's revenue for the quarter was up 391.6% on a year-over-year basis. During the same period last year, the business posted ($3.37) EPS.
View SAGE Therapeutics' earnings history.

17 brokers have issued twelve-month price targets for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $82.11 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts' price targets for SAGE Therapeutics.

Media headlines about SAGE stock have trended somewhat positive on Monday, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about SAGE Therapeutics.

Some companies that are related to SAGE Therapeutics include Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Bausch Health Companies (BHC), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE) and Schrodinger (SDGR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.12%), Comerica Bank (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%), XTX Markets LLC (0.01%) and Westside Investment Management Inc. (0.01%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and Nisa Investment Advisors LLC.
View insider buying and selling activity for SAGE Therapeutics.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, XTX Markets LLC, Zurcher Kantonalbank Zurich Cantonalbank , Nelson Van Denburg & Campbell Wealth Management Group LLC, Comerica Bank, and Westside Investment Management Inc.. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $46.42.

SAGE Therapeutics has a market capitalization of $2.41 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

The official website for SAGE Therapeutics is www.sagerx.com.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]